{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:56:25Z","timestamp":1786978585282,"version":"build-2736575974"},"reference-count":39,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Romanian National Society of Medical Oncology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Immune checkpoint inhibitors (ICIs) have moved from the metastatic setting into neoadjuvant, adjuvant, and fully perioperative strategies across several solid tumors. This shift has created a new clinical interface between medical oncology, surgery, anesthesia, pathology and postoperative care because immune activation may improve pathological response and survival while also generating immune-related adverse events (irAEs) that mimic or aggravate perioperative complications. Methods: We conducted a scoping review according to PRISMA-ScR. PubMed\/MEDLINE and Web of Science were searched for studies published between 2016 and 2026 that evaluated adult patients with solid tumors receiving ICIs in relation to surgery. Thirty-three studies were included and synthesized descriptively across surgical feasibility, perioperative safety, irAEs, anesthetic considerations, and oncological outcomes. Results: The strongest evidence was found in resectable non-small-cell lung cancer, where neoadjuvant or perioperative ICI-based regimens improved pathological response and, in several trials, event-free or overall survival. Evidence in triple-negative breast, bladder, gastric\/gastroesophageal junction, and ovarian cancers supported broader applicability but remained heterogeneous, with variable efficacy across tumor types and treatment regimens. Surgery following ICI exposure was generally feasible, without a consistent increase in postoperative mortality. However, pneumonitis, myocarditis, endocrinopathies, hepatitis, colitis, and cytokine release syndrome may mimic conventional postoperative complications. Direct evidence comparing anesthetic or perioperative management strategies was scarce. Conclusions: Perioperative ICI-based therapy is no longer an experimental concept, but its safe implementation requires structured preoperative screening, individualized surgical timing, organ-specific toxicity surveillance, careful corticosteroid decision-making, and close multidisciplinary communication. Future prospective studies should integrate standardized perioperative endpoints, anesthesia-related variables, biomarker-driven risk stratification, and long-term oncological outcomes.<\/jats:p>","DOI":"10.3390\/cancers18162654","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:42:17Z","timestamp":1786974137000},"page":"2654","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Care of Cancer Patients Treated with Immune Checkpoint Inhibitors: Current Evidence and Clinical Considerations\u2014A Scoping Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2381-5577","authenticated-orcid":false,"given":"Ioana Roxana","family":"Codru","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania"},{"name":"Anesthesia and Intensive Care Department, Clinical Emergency Hospital of Sibiu, 550245 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-8825","authenticated-orcid":false,"given":"Liliana","family":"Vecerzan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania"},{"name":"Oncology Department, Clinical Military Emergency Hospital of Sibiu, 550024 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/curroncol30040280","article-title":"Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives","volume":"30","author":"Lazzari","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non\u2013Small-Cell Lung Cancer\u2014A Multicenter Single-Arm Phase II Trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1038\/s41467-025-63696-5","article-title":"Tumor Immune Dynamics and Long-Term Clinical Outcome of Stage IIIA NSCLC Patients Treated with Neoadjuvant Chemoimmunotherapy","volume":"16","author":"Schmid","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116165","DOI":"10.1016\/j.ejca.2025.116165","article-title":"Long-Term Outcomes of Preoperative Nivolumab with or without Relatlimab in Patients with Resectable Non-Small-Cell Lung Cancer (NEOpredict-Lung)","volume":"233","author":"Cuppens","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab Compared with Neoadjuvant Chemotherapy Alone in Patients with Early-Stage Non-Small-Cell Lung Cancer (KEYNOTE-671): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.annonc.2025.11.017","article-title":"Perioperative Tislelizumab plus Neoadjuvant Chemotherapy for Patients with Resectable Non-Small-Cell Lung Cancer: Final Analysis of the Randomized RATIONALE-315 Trial","volume":"37","author":"Wang","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Elias, A.W., Kasi, P.M., Stauffer, J.A., Thiel, D.D., Colibaseanu, D.T., Mody, K., Joseph, R.W., and Bagaria, S.P. (2017). The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00121"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Codru, I.R., and Vecerzan, L. (2025). When and for Whom Does Intensive Care Unit Admission Change the Prognosis in Oncology?\u2014A Scoping Review. Cancers, 17.","DOI":"10.3390\/cancers17223636"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/cas.70307","article-title":"Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis","volume":"117","author":"Takahashi","year":"2026","journal-title":"Cancer Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-25-0369","article-title":"A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer\u2014The MONEO Study","volume":"31","author":"Alsina","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2513109","DOI":"10.1080\/2162402X.2025.2513109","article-title":"Peripheral Memory B Cell Population Maintenance and Long-Term Survival after Perioperative Chemoimmunotherapy in NSCLC (NADIM Trial)","volume":"14","author":"Nadal","year":"2025","journal-title":"Oncoimmunology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jtcvs.2021.02.099","article-title":"Perioperative Outcomes of Pulmonary Resection after Neoadjuvant Pembrolizumab in Patients with Non\u2013Small Cell Lung Cancer","volume":"163","author":"Tong","year":"2022","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00262-024-03764-9","article-title":"Long-Term Survivals of Immune Checkpoint Inhibitors as Neoadjuvant and Adjuvant Therapy in DMMR\/MSI-H Colorectal and Gastric Cancers","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Liu, W., Ou, C., Xue, R., Yang, X., Ye, Y., Wang, X., and Xie, J. (2024). Opioid\u2212free Anesthesia Attenuates Perioperative Immunosuppression by Regulating Macrophages Polarization in Gastric Cancer Patients Treated with Neoadjuvant PD-1 Inhibitor. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1438859"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.3390\/curroncol30080540","article-title":"Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease","volume":"30","author":"Sandbank","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_20","first-page":"E1068","article-title":"Association of Preoperative Immune Checkpoint Inhibitor Therapy with Cardiopulmonary Instability and Organ Injury after High-Risk Surgery","volume":"6","author":"Tang","year":"2024","journal-title":"Crit. Care Explor."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11912-022-01202-6","article-title":"Cancer Immunotherapies: What the Perioperative Physician Needs to Know","volume":"24","author":"Ackerman","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2217\/imt-2020-0329","article-title":"Delayed Cytokine Release Syndrome after Neoadjuvant Nivolumab: A Case Report and Literature Review","volume":"13","author":"Ciner","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cao, Y., Tian, Y., and Li, L. (2025). Perioperative Immune Checkpoint Inhibitors in Elderly Patients with Resectable NSCLC: A Systematic Review and Meta-Analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1589846"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Guo, X., Wang, J., Li, D., Wang, B., Zhu, H., and Guo, H. (2024). Case Report: The Outcomes of Neoadjuvant Immunotherapy Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma: Case Series and Literature Review. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1467755"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cllc.2024.03.008","article-title":"Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study","volume":"25","author":"Pan","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ezaf351","DOI":"10.1093\/ejcts\/ezaf351","article-title":"Neoadjuvant Chemoimmunotherapy in Non-Small-Cell Lung Cancer Patients: Effects on Pulmonary Function and Incidence of Postoperative Pulmonary Complications-A Multicentre Real-World Study","volume":"67","author":"Zhang","year":"2025","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.athoracsur.2025.03.033","article-title":"Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-Small Cell Lung Cancer","volume":"120","author":"Chen","year":"2025","journal-title":"Ann. Thorac. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2670145","DOI":"10.1080\/07853890.2026.2670145","article-title":"Neoadjuvant Immunochemotherapy and Postoperative Acute Hypoxemic Respiratory Failure in Thoracic Surgery: A Multicentre Cohort Study","volume":"58","author":"Tan","year":"2026","journal-title":"Ann. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1038\/s41591-025-03979-y","article-title":"Perioperative Pembrolizumab, Trastuzumab and FLOT in HER2-Positive Localized Esophagogastric Adenocarcinoma: A Phase 2 Trial","volume":"31","author":"Stein","year":"2025","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.24.00795","article-title":"Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","article-title":"Adjuvant Immunotherapy in Patients with Resected Gastric and Oesophagogastric Junction Cancer Following Preoperative Chemotherapy with High Risk for Recurrence (YpN+ and\/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE Study","volume":"36","author":"Lordick","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/joim.70073","article-title":"Perioperative Immune Checkpoint Inhibitor Therapy across Tumors: Insights and Shared Lessons from a Rapidly Evolving Field","volume":"299","author":"Matikas","year":"2026","journal-title":"J. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000503166","article-title":"Intraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer","volume":"29","author":"Hu","year":"2020","journal-title":"Med. Princ. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus Ipilimumab for Potentially Resectable Hepatocellular Carcinoma: Long-Term Efficacy and Biomarker Exploration","volume":"84","author":"Lin","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00262-024-03802-6","article-title":"The Short-Term Efficacy of Neoadjuvant SOX versus SOX plus Immune Checkpoint Inhibitor Following Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer: A Multicenter Retrospective Cohort Study in China","volume":"73","author":"Cui","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Moldovan, B., Adam, I.-I., Pisic\u0103, R.-M., Untaru, V., Stoica, D., \u0218pac, A., Modrigan, I., Ursu, M., Jupoiu, L., and Fr\u00e2ncu, A. (2024). Takotsubo Cardiomyopathy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for a Recurrent Colon Cancer: A Life-Threatening Complication. Diagnostics, 14.","DOI":"10.3390\/diagnostics14212402"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Moldovan, B., Costache, V.S., Modrigan, I., Farcas, F., Banu, E., Untaru, V., Stoica, D., Crisan, M., Popianas, A., and Pisica, R.-M. (2023). Inferior Vena Cava (IVC) Resections without Reconstruction in Renal Tumors: Two Case Reports. Diagnostics, 13.","DOI":"10.3390\/diagnostics13101759"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00432-024-05967-0","article-title":"Frequency and Distribution Pattern of Lymph Node Metastasis after Neoadjuvant Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma","volume":"150","author":"Zhou","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1097\/JS9.0000000000001468","article-title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Following Laparoscopic Gastrectomy for Gastric Cancer: A Multicentre Real-World Clinical Study","volume":"110","author":"Sun","year":"2024","journal-title":"Int. J. Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2654\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:54:32Z","timestamp":1786974872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":39,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162654"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162654","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}